This paper is in the following e-collection/theme issue:

Corrigenda and Addenda (15)

Published on in Vol 6, No 3 (2022): March

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/38002, first published .
Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

Correction: Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

Authors of this article:

Volker Limmroth1 Author Orcid Image ;   Kirsten Bayer-Gersmann2 Author Orcid Image ;   Christian Mueller3 Author Orcid Image ;   Markus Schürks3 Author Orcid Image
Article Authors Cited by Tweetations (4) Metrics

    Corrigenda and Addenda

    1Clinic for Neurology and Palliative Medicine, Municipal Hospital Köln-Merheim, Cologne, Germany

    2Institut Dr. Schauerte, Munich, Germany

    3Bayer Vital GmbH, Leverkusen, Germany

    Corresponding Author:

    Markus Schürks, MSc, MD

    Bayer Vital GmbH

    Medical Affairs, Neurology, Immunology & Ophthalmology

    Leverkusen, 51368

    Germany

    Phone: 49 214 30 51455

    Email: markus.schuerks@bayer.com



    In “Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study” (JMIR Form Res 2022;6(3):e31972) the authors noted one error.

    In the originally published article, Figure 2 appeared incorrectly (as shown in the Multimedia Appendix 1).

    The correct Figure 2 is provided below.

    The correction will appear in the online version of the paper on the JMIR Publications website on March 17, 2022, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.

    ‎
    Figure 2. (A) Compliance overall and by gender and age group, (B) patients categorized by percentage of interferon β-1b injections missed (based on an expected frequency of 1 injection every other day), and (C) adherence overall and by gender and age group, analyzed (i) prospectively and (ii) retrospectively. Compliance at 6 and 12 months was assessed in patients with ≥6 and ≥12 months of injection-related data, respectively. In the box and whisker plots, the colored bars indicate median and IQR, the whiskers indicate minimum and maximum values, and the white circles indicate the mean.
    Multimedia Appendix 1

    Originally published Figure 2.

    PNG File , 95 KB

    This is a non–peer-reviewed article. submitted 15.03.22; accepted 15.03.22; published 17.03.22.

    Copyright

    ©Volker Limmroth, Kirsten Bayer-Gersmann, Christian Mueller, Markus Schürks. Originally published in JMIR Formative Research (https://formative.jmir.org), 17.03.2022.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.